BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine (HiDAC) chemotherapy in a phase 2a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2021-04, Vol.127 (8), p.1246-1259
Main Authors: Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraham, Michal, Peled, Amnon, Shaw, Stephen, Bohana‐Kashtan, Osnat, Sorani, Ella, Pereg, Yaron, Foley‐Comer, Adam, Oberkovitz, Galia, Lustig, Tzipi M., Glicko‐Kabir, Irit, Aharon, Arnon, Vainstein‐Haras, Abi, Kadosh, Shaul E., Samara, Emil, Al‐Rawi, Ahmed N., Pemmaraju, Naveen, Bueso‐Ramos, Carlos, Cortes, Jorge E., Andreeff, Michael
Format: Article
Language:English
Subjects:
acute myelogenous leukemia (AML)
Acute myeloid leukemia
Anticancer properties
BL‐8040
Bone marrow
Chemotherapy
CXCR4
CXCR4 protein
Cytarabine
Leukemia
Leukocytes (neutrophilic)
Myeloid leukemia
Oncology
Patients
Peripheral blood
Platelets
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine (HiDAC) chemotherapy in a phase 2a study of patients with relapsed and refractory AML. Methods Forty‐two patients received treatment with BL‐8040 monotherapy for 2 days followed by a combination of BL‐8040 with HiDAC for 5 days. Six escalating BL‐8040 dose levels were investigated (0.5, 0.75, 1.0, 1.25, 1.5, and 2.0 mg/kg), and 1.5 mg/kg was selected as the dose for the expansion phase (n = 23). Results BL‐8040 in combination with HiDAC was safe and well tolerated at all dose levels. Clinical response was observed with BL‐8040 doses ≥1.0 mg/kg. The composite response rate (complete remissions plus complete remissions with incomplete hematologic recovery of platelets or neutrophils) was 29% (12 of 42) in all patients and 39% (9 of 23) in the 1.5‐mg/kg phase. The median overall survival was 8.4 months for all patients, 10.8 months in the 1.5‐mg/kg phase, and 21.8 months for responding patients in the 1.5‐mg/kg cohort. Two days of BL‐8040 monotherapy triggered the mobilization of blasts into peripheral blood, with significantly higher mean fold‐changes in responders versus nonresponders. This was accompanied by a decrease in bone marrow blasts. Conclusions The current results demonstrate the efficacy of CXCR4 targeting with BL‐8040 and support continued clinical development in acute myelogenous leukemia. BL‐8040 is a high‐affinity CXCR4 inhibitor. Combined with cytarabine, BL‐8040 treatment results in improved composite complete response rates and median overall survival in hard‐to‐treat patients with relapsed/refractory acute myelogenous leukemia.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33338